Furthermore, risk of hypoglycemia was equal between DPP-4 inhibition vs. SGLT2 inhibition (115, 117) or higher for SGLT2 inhibition (116), whereas all studies showed that body weight is reduced by SGLT2 inhibitors but not by sitagliptin and adverse events, such as genital infections, are higher for SGLT-2 inhibitors than for sitagliptin. This evidence concerns the gene SLC5A2 and Hypoglycemia.